- Home
- BCAT vs CRVS Comparison
BCAT vs CRVS Comparison
Compare BCAT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | CRVS |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BCAT | CRVS |
|---|---|---|
| Price | $14.89 | $16.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 821.6K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.91 | $2.54 |
| 52 Week High | $15.58 | $26.95 |
Technical Indicators
Market Signals| Indicator | BCAT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 48.45 |
| Support Level | $14.76 | $17.27 |
| Resistance Level | $15.27 | $19.98 |
| Average True Range (ATR) | 0.18 | 1.29 |
| MACD | -0.01 | -0.83 |
| Stochastic Oscillator | 49.99 | 0.00 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).